Improvement of ACK1-targeted therapy efficacy in lung adenocarcinoma using chloroquine or bafilomycin A1

BACKGROUND: Activated Cdc42-associated kinase 1 (ACK1) is a promising druggable target for cancer, but its inhibitors only showed moderate effects in clinical trials. The study aimed to investigate the underlying mechanisms and improve the antitumor efficacy of ACK1 inhibitors. METHODS: RNA-seq was...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Jinhong, Cao, Kui, Zhao, Meng, Ma, Keru, Jiang, Xiangyu, Bai, Yuwen, Ling, Xiaodong, Ma, Jianqun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843944/
https://www.ncbi.nlm.nih.gov/pubmed/36647009
http://dx.doi.org/10.1186/s10020-023-00602-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843944/
https://www.ncbi.nlm.nih.gov/pubmed/36647009
http://dx.doi.org/10.1186/s10020-023-00602-z

Ejemplares similares